Drug Profile
Peginterferon alfa-2a biosimilar - Biogenomics
Alternative Names: Peginterferon alfa-2a biosimilar - Biogenomics; Peginterferon alpha-2a - BiogenomicsLatest Information Update: 17 Sep 2021
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
- Mechanism of Action Interferon alfa 2a stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hepatitis-C in India (SC, Injection)
- 16 Jan 2014 Peginterferon alfa-2a - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
- 15 Jan 2014 Clinical trials in Hepatitis C in India (SC)